Pericardial Patches Segmentation
Type (Synthetic Pericardial Patches, Biological Pericardial Patches)
In pericardial patches market, biological pericardial patches segment is projected to dominate revenue share of around 88% by the end of 2037. These patches are preferred owing to their superior biocompatibility with low chances of immune rejection compared to the synthetic alternative. This wide use in cardiac and vascular surgery underlines their clinical effectiveness. In January 2020, Tendyne marked a milestone by completing the first commercial implantation of its Transcatheter Mitral Valve System using a biological patch, furthering minimally invasive treatments. The preference for these products points toward their important position in modern surgical applications.
Source (Bovine, Porcine, Equine, Others)
By 2037, bovine segment is set to dominate pericardial patches market share of over 40.4%. The growth of the segment can be attributed to the performance that bovine materials display while being used in pericardial applications, such as cardiovascular repairs. Furthermore, with enhancements in processing techniques, durability and compatibility also improve, making them adaptable for medical use. Their application in a variety of surgical procedures underlines their growing relevance. The growth in this segment reflects the demand for dependable and biocompatible materials in healthcare.
Our in-depth analysis of the pericardial patches market includes the following segments
|
Type |
|
|
Source |
|
|
Application |
|
|
End user |
|
